Newsletters

PMC Series: Interview with Colin Hill, Chairman, CEO and Co-Founder of GNS Healthcare

Slone Partners’ 2018 PMC Interview Series enters its 4th week with an exclusive, in-depth interview with Colin Hill, the Chairman, CEO...

PMC Series: Interview with William Dalton, Ph.D M.D., Founder and Executive Chair of M2Gen

Slone Partners’ 2018 PMC Interview Series continues with an exclusive, in-depth interview with William Dalton Ph.D M.D., the Founder and Executive...

PMC Series: Interview with David King, Chairman and CEO of LabCorp

Slone Partners’ 2018 PMC Interview Series continues with an exclusive, in-depth interview with David P. King, the Chairman and CEO of...

PMC Series: Interview with Daniel O’Day, CEO of Roche Pharmaceuticals

Slone Partners’ 2018 PMC Interview Series debuts with an exclusive, in-depth interview of Daniel O’Day, the CEO of Roche Pharmaceuticals. A...

Leadership Series: Interview with Laurie Halloran, Founder and CEO of Halloran Consulting Group

In this quarter’s newsletter, we exclusively interview Laurie Halloran, Founder and CEO of her pioneering Halloran Consulting Group, which assists life...

Leadership Series: Insights, Culture As A Cornerstone

How To Activate Board Members and Senior Executives To Build Thriving Cultural Environments For Scientific Healthcare Companies & Beyond As part...

Leadership Series: Interview with Harry Glorikian, Partner at New Ventures Funds and Influential Global Business Expert

As part of Slone Partners’ ongoing series of exclusive interviews with healthcare pioneers, we’re delighted to present Harry Glorikian, a global healthcare...

Leadership Series: Interview with Kimberly Popovits, Chairman of the Board, CEO and President of Genomic Health

As part of our ongoing series of interviews with healthcare pioneers, we’re delighted to present Kimberly Popovits, Chairman of the Board,...

PMC Series: Exclusive Interview with Joydeep Goswami, PhD, MBA, President, Clinical NGS and Oncology at Thermo Fisher Scientific

Slone Partners: How does someone become the President of Clinical Next-Generation Sequencing and Oncology of a $20 billion company like Thermo...